Replimune Group (REPL) risk factors

57 risks, 7 new, 7 dropped, 11 reworded since the prior year. RP1’s resubmitted BLA faces unresolved FDA concerns and potential advisory committee scrutiny in late July 2026.

57 risks. Replimune is entirely dependent on developing and commercializing its lead oncolytic immunotherapy candidate RP1 and proprietary RPx platform. The company faces high capital requirements, relying on $483.8 million in cash reserves at March 31, 2025. Internal manufacturing operations rely on a single 63,000 square foot facility in Framingham, Massachusetts.